Leveraging Drug-Gene Interaction Information for Personalized Hypertension Drug Molecule Discovery
Odifentse Mapula-e Lehasa, Uche A. K. Chude‐Okonkwo · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · 2024
Aims: To examine whether novel lead hypertension molecules can be used in the personalized treatment of hypertension. Background/Introduction: Hypertension is a modifiable condition that affects over 1 billion adults worldwide. Maintaining a healthy blood pressure is vital for overall health, especially given that hypertension is a primary risk factor for developing cardiovascular conditions. However, some individuals have resistant hypertension, which may be due to variations in genetic expression, making standard hypertension treatments ineffective. Objective: The integration of genetic data into the personalized optimization of novel hypertension drugs is demonstrated. Method: This research created coding criteria for drug-gene recommendations based on the genomic profiles of ten pseudo-patients. The genomic data of these patients was created using chromosome and hypertension-implicated gene sequences from the NCBI National Library of Medicine database. Results and Discussion: This study uses the proposed drug recommendation criteria to recommend novel hypertension lead molecules to each patient based on their gene expression profiles. Conclusion: This study’s patient-centric drug prescription approach integrates patient gene expression data with drug-gene interaction data and recommends novel hypertension drugs most suitable for each patient. Variations in patient gene expression explain the diverse treatment responses inherent across hypertensive patients, thus necessitating a personalized approach to their drug prescription. Future studies can investigate the challenges of ethical, technological, and technical expertise that may affect the clinical implementation of personalized drug prescription recommendation systems.